Early Phase Clinical Trials Market Trends
Category Intelligence on Early Phase Clinical Trials covers the following
- Information relating to market, supply, cost, and pricing analysis
- Hard to find data on cost and TCO models, supplier details, and performance benchmarks
- Macroeconomic and regional trends impacting cost, supply, and other market dynamics
- Category-specific negotiation and sourcing advice
Industry Outlook & Drivers
Global Market Outlook on Early Phase Clinical Trials
- The current phase I clinical trial market is valued at $14 billion and is expected to grow at a CAGR of 3–4 percent until 2018. The comparatively slow growth rate is a result of trials being conducted on a smaller population (20 -40) of volunteers, unlike late stage trials
- The FDA and other local regulatory bodies are providing further guidance and revisions for data and safe monitoring for early phase trials as a result of trial failures. The average per study cost for a Phase I trial is valued at $4 million with clinical procedure costs being the highest at $476,000 which contributes to 22.2 percent of the overall trial cost as of 2015
- South Korea is found to be the most attractive early phase destination based on the availability of global and regional suppliers, patient pool and regulatory scenario of the country
US and Europe will remain key regions for early phase trials holding greater than 70 percent market share. However, South Korea with its regulatory flexibility is an emerging destination with a CAGR of 8.2 percent, almost twice as rest of the world
Early PhaseCRO Market and Spend by Therapeutic Area
- The outsourced phase I market is estimated at $8 Billion and is growing at a CAGR of 3-4 percent. This market is comprised by CROs, Research Centers, Academic Institutes etc
- From the entire outsourced Phase I spend of $8 billion, pharma spends approximately $5.5billion with CROs for carrying out their early phase studies while the rest is carried out in-house or in collaboration with academic institutions
- The FDA and other local regulatory bodies are providing further guidance and revisions for data and safe monitoring for early phase trials, i.e. phase I trial, as a result of trial failures. The average per study cost for a phase I trial is valued at $4 million with clinical procedure costs being the highest at $476,000 which contributes to 22.2 percent of the overall trial cost
Growth Drivers and Constraints
High Trial Complexity:
- Early phase trials has the highest protocol complexity (14 percent) and a high work burden of 9.5 percent, since it involves healthy volunteers and patients. In-house facilities needs to have sufficient beds, equipment's and access to patient to carry out these trials.
Patient Recruitment & Regulations
- Country-specific regulations and access to patient populations can be managed efficiently by suppliers as they have local presence and have dedicated patient database
- Due to loss of patents for many drugs in the upcoming years and increase in R&D spend, pharma are looking to reduce costs. Reduction in fixed costs over the long run of the Phase I Unit can be obtained through outsourcing
High Supplier Fees
- High short-term R&D costs due to high supplier fees can be a problem over a short-term period; however, can result in savings over the long term.
- Provisions for unforeseen events (early termination of a project) could cause a sudden pause in trials creating a major delay in trial conduct.
- If a supplier with the right operational capability is not selected, they will be unable to deliver; resulting in increased need for pharma to oversee supplier operations
Complexity of early phase trials, involving both patient and healthy volunteers studies, is the main driver of outsourcing. Though cost reduction is seen over the longer term, high supplier fees initially and quality issues is still a challenge.
Changing regulatory scenario, CRO dynamics, risk sharing models, technologies are the key areas impacting early phase trial conduct. Buyers have to ensure suppliers have regional regulatory expertise, therapeutic, operational capability and innovative technologies to handle the complex trials. Upon assurance, a full-service strategic partnership could be formed.
- Large CROs were seen cutting down on their in-house facilities (e.g.: Parexel, INC Research, IQVIA) due to a slip in early development revenues in 2012. As a result of increased need for specialized population, Phase I CRO businesses saw an upturn (e.g. PPD’s new 24 bed unit in Las Vegas) to expand early development service offering
- They open up or acquire specialized Phase I units based on therapeutic areas to match up the competency of these niche players and drive revenues
- Regulations are revised frequently. These revisions are result of either a trial failure adding more stringency or relaxation to improve recruitment rates.
- Contribution of trials from Russia, South Korea etc., will increase in the future due to competitive price and patient availability. This has caused suppliers to expand in these regions
- A new rule states that clinical trials which test drugs for Indian market must include Indian subjects in their trial . This will affect the recruitment procedures by CROs for drug trials that are intended for the Indian market.
- Adaptive trials leads to increased flexibility of clinical trials enabling parameters such as sample size, patient population, dosing to be adjusted as the trial progresses.
- Early terminations of clinical trials futility or sample size estimation could help in saving a sponsor between $100-200 million on the aggregate costs
- Outsourcing on a full-service basis based on therapeutic area and functions, by having a risk sharing model between CRO–Pharma is emerging at an adoption rate of 15 percent
- The clinical research market has a growing trend to evaluate predictive biomarkers in enriched patient populations in early phase trials (Phase I–IIa)
- Rapid evaluation of drugs, validate multiple predictive biomarkers, minimized exposure of patients to ineffective therapies, accelerated drug approval in molecularly defined populations (E.g. Personalized Medicine)